Sqz Biotechnologies Co. (SQZB)
Market Open
12 Aug, 14:35
OTC PINK OTC PINK Primary $
0. 02
0
0%
$
707.79K Market Cap
- P/E Ratio
- Div Yield
100 Volume
- Eps
$ 0.02
Previous Close Want to track SQZB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SQZB trading today higher at $0.02, an increase of 0% from yesterday's close, completing a monthly increase of 0% or $0. Over the past 12 months, SQZB stock gained 0%.
SQZB is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Sqz Biotechnologies Co. has completed 1 stock splits, with the recent split occurring on Jul 07, 2023.
The company's stock is traded on one exchange.
Sqz Biotechnologies Co. (SQZB) FAQ
What is the stock price today?
The current price is $0.02.
On which exchange is it traded?
Sqz Biotechnologies Co. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is SQZB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 707.79K.
Has Sqz Biotechnologies Co. ever had a stock split?
Sqz Biotechnologies Co. had 1 splits and the recent split was on Jul 07, 2023.
Sqz Biotechnologies Co. Profile
| Biotechnology Industry | Healthcare Sector | Howard Bernstein CEO | OTC PINK Exchange | 78472W104 CUSIP |
| US Country | 53 Employees | - Last Dividend | 7 Jul 2023 Last Split | - IPO Date |
Overview
SQZ Biotechnologies Company is at the forefront of innovative therapeutic solutions, distinguished as a clinical-stage biotechnology entity focused on the development of novel cell therapies. Its aim is to address a wide range of severe health conditions encompassing cancer, autoimmune disorders, infectious diseases, and beyond. Established in 2013 and rooted in Watertown, Massachusetts, SQZ Biotechnologies is pioneering advancements in cell therapy with the ambition to transform patient care on a global scale.
Products and Services
- SQZ-PBMC-HPV: Representing the culmination of the company's SQZ Antigen Presenting Cells platform, SQZ-PBMC-HPV emerges as a leading product candidate currently under Phase I clinical trials. Developed as both a monotherapy and in combination with immuno-oncology agents, this innovative therapy targets HPV16+ advanced or metastatic solid tumors. The list of cancers addressed includes cervical, head and neck, anal, penile, vulvar, and vaginal cancer, marking a significant stride in oncological therapeutics.
- SQZ-AAC-HPV: Parallel to the development of SQZ-PBMC-HPV, SQZ-AAC-HPV also focuses on the treatment of HPV16+ advanced or metastatic solid tumors. This product candidate, too, is evaluated under a Phase I clinical trial, exploring its efficacy both as a single treatment option and in combination with immune-oncology agents. Its progression denotes SQZ Biotechnologies' commitment to broadening its arsenal against cancer.
- Additional Platforms in Development: The innovation pipeline of SQZ Biotechnologies doesn't stop with its leading contenders. Other noteworthy platforms undergoing development include SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers. These platforms underline the company's dedication to harnessing the full potential of cell therapy, endeavoring not just to combat but also to redefine the treatment landscapes of various serious conditions.
Contact Information
Address: 200 Arsenal Yards Boulevard
Phone: 617 758 8672
Website: https://www.sqzbiotech.com
